Eric Lefkofsky Sells 132,591 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 132,591 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $6,577,839.51. Following the sale, the chief executive officer owned 2,098,130 shares in the company, valued at approximately $104,088,229.30. This represents a 5.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Up 9.1%

TEM opened at $72.69 on Friday. The company has a fifty day moving average of $52.93 and a two-hundred day moving average of $51.36. The stock has a market capitalization of $13.12 billion, a price-to-earnings ratio of -50.48 and a beta of 3.58. Tempus AI, Inc. has a fifty-two week low of $40.77 and a fifty-two week high of $104.32. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. The business had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.22) EPS. On average, research analysts expect that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Institutional Investors Weigh In On Tempus AI

Large investors have recently bought and sold shares of the company. Royal Bank of Canada boosted its stake in shares of Tempus AI by 201.2% in the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after acquiring an additional 17,359 shares during the last quarter. Rhumbline Advisers acquired a new position in Tempus AI in the 1st quarter valued at $116,000. Prudential Financial Inc. purchased a new position in Tempus AI in the 2nd quarter valued at $276,000. Russell Investments Group Ltd. lifted its holdings in Tempus AI by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock valued at $415,000 after purchasing an additional 1,146 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Tempus AI by 2,926.6% during the 2nd quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock worth $13,446,000 after purchasing an additional 204,629 shares during the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TEM shares. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research note on Friday, July 31st. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. TD Cowen reissued a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. BTIG Research upped their price objective on shares of Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Freedom Capital raised shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $65.69.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
• Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
• Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
• Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.